XML 45 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation (Tables)
6 Months Ended
Jun. 30, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity
A summary of the stock option activity under the Company’s equity plans and inducement awards, for the six months ended June 30, 2021 is as follows:
(number of shares in millions)Number
of
Shares
Weighted
Average
Exercise
Price
Options outstanding at December 31, 20205.2 $23.24 
Options granted— $— 
Less:
Options exercised(2.1)$22.93 
Options canceled or expired(0.1)$24.81 
Options outstanding at June 30, 20213.0 $23.42 
Options exercisable at June 30, 20212.4 $26.25 
Schedule of Restricted Stock Unit Activity
A summary of the RSU activity under the Company’s equity plans and inducement awards, including RSU awards with performance metrics, for the six months ended June 30, 2021 is as follows:
(number of shares in millions)Number
of
Shares
Weighted
Average
Grant Date
Fair Value
RSUs outstanding at December 31, 20203.2 $20.56 
RSUs granted1.5 $29.89 
Less:
RSUs vested(0.1)$18.88 
RSUs canceled(0.6)$24.54 
RSUs outstanding at June 30, 20214.0 $23.72 
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Loss was allocated as follows:
Three months ended
June 30,
Six months ended
June 30,
(in millions)2021202020212020
Cost of molecular diagnostic testing$0.4 $0.3 $0.7 $0.7 
Cost of pharmaceutical and clinical services— 0.1 0.1 0.2 
Research and development expense1.0 1.2 2.5 2.3 
Selling, general, and administrative expense7.5 0.3 14.6 6.2 
     Total stock-based compensation expense$8.9 $1.9 $17.9 $9.4